1
likes
0
comments
daily view 0
monthly view 0

Share

Live Analytics

Comments 0

India Approves First Dengue Vaccine QDENGA for People Aged 4 to 60 Years Analytics Table

Income Estimates for India Approves First Dengue Vaccine QDENGA for People Aged 4 to 60 Years

Based on this YouTube video's total view count of 1.08K views and industry-standard rates, the estimated total earning is $1 - $2 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

About India Approves First Dengue Vaccine QDENGA for People Aged 4 to 60 Years

Explore India Approves First Dengue Vaccine QDENGA for People Aged 4 to 60 Years with 1,087 views, 1 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.

India has approved a new dengue vaccine for ages 4 to 60. Learn what this means for dengue prevention efforts across the country. This update covers the regulatory approval of the latest dengue vaccine in India, detailing the age eligibility criteria and the context surrounding the decision. If you are tracking public health trends or looking for information on emerging medical solutions for mosquito-borne illnesses, this summary provides the essential facts. Rising infection rates have made dengue control a priority, and this vaccine approval is a key development in public health policy. We examine the scope of the new vaccine and who qualifies for it based on the latest government announcements. Understanding these changes helps clarify how the healthcare system is responding to the current increase in cases. Subscribe for weekly public health updates, and comment below on what medical news topics you want covered next. In this video, we explain: What is QDENGA? Who can take the dengue vaccine? Vaccine eligibility (4–60 years) Two-dose vaccination schedule Clinical trial results and effectiveness WHO recommendation Countries where QDENGA is already available Why this approval is a major breakthrough for India Takeda's Phase III clinical trials involving over 20,000 participants demonstrated: ✅ 80.2% efficacy against confirmed dengue ✅ 90.4% protection against dengue-related hospitalization ✅ Long-term protection for up to seven years This approval is expected to strengthen India's fight against dengue, one of the country's fastest-growing mosquito-borne diseases. 📢 Stay updated with the latest health, medical, and India news by subscribing to our channel. #denguevaccine #QDENGA #indianews #healthnews #takeda #dcgi #who #medicalnews #breakingnews #Piotv Follow us: Official website: https://piotv.com/ Twitter: https://x.com/piotv1 Facebook: https://www.facebook.com/IndianDiasporaTV Instagram: https://www.instagram.com/piotv0/

About YouTube Real-Time View Count

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.

Embed Widget

Parameters:

  • fullscreen=true - Fullscreen counter
  • graph=true - Live graph chart
  • counter=0/1/2 - Select counter (0=likes, 1=views, 2=comments)
URL

Click to copy the embed URL to your clipboard